Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
ostrich antibodies to SARS-CoV-2
- Development stage
- Preclinical
- Lead developer
- Ostrich Pharma USA
- Modality
- Antibody-Based Therapeutics
- Administration
- Intranasal, Oral, Topical
01
Overview
Ostrich antibodies to SARS-CoV-2 are **polyclonal egg yolk immunoglobulin Y antibodies** developed by Ostrich Pharma USA for the prevention and potential treatment of COVID-19. The product is generated by immunizing ostriches with SARS-CoV-2 spike-related antigens, including pseudovirus or spike protein, and then harvesting and purifying neutralizing IgY from ostrich eggs. These antibodies are intended to bind the **SARS-CoV-2 spike protein** and inhibit viral attachment to the **human angiotensin-converting enzyme 2 receptor**, thereby blocking viral entry at mucosal surfaces. Reported prophylactic formats include **nasal drops**, as well as antibody-impregnated face masks and candies, with clinical evaluation initiated in Japan for prevention of hospital-acquired coronavirus infection.
- Other names
- ostrich antibodies to SARS-CoV-2anti-SARS-CoV-2 ostrich IgY antibodiesanti-SARS-CoV2 ostrich IgY antibodiesanti-SARS-CoV 2 ostrich IgY antibodiesostrich polyclonal IgY antibodies against SARS-CoV-2
02
Targets
SARS-CoV-2 spike
Beyond the preview
Go deeper on ostrich antibodies to SARS-CoV-2.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on ostrich antibodies to SARS-CoV-2.